

**REQUEST FOR PUBLICATION APPROVAL FOR SCIENTIFIC MANUSCRIPTS**

PUBLICATION TRACKING NUMBER  
(To be assigned at DCCPS OD-level)

**SECTION I - TO BE COMPLETED BY AUTHOR**

1. TITLE OF PUBLICATION: Early detection of circulating tumor material and digital imaging for management of pancreatic cancer

TYPE (Circle One): **scientific manuscript** editorial letter to editor book chapter other (explain)

2. AUTHOR(S): Radim Moravec, Rao Di

All authors have approved this manuscript

3. SUBMITTED FOR PUBLICATION IN (Title of Journal or Other Publication):

IS THERE A PUBLICATION PROCESSING FEE? Yes  No  AMOUNT: \$

4. REQUEST BY	a. NAME	b. TITLE	c. DATE
	d. PROGRAM/BRANCH	e. BUILDING/ROOM	f. PHONE NUMBER

5. ASSOCIATED GRANT OR CONTRACT NUMBER (If Applicable):


6. ASSOCIATED DCCPS INITIATIVE(S) (If Applicable):

7. ADDITIONAL CONSIDERATIONS (Please check all that apply and describe in space below or attach comments)

- Controversial
- Major Scientific Development
- Anticipate Media Attention
- Area of HHS Special Interest (e.g., Obesity, Health Disparities)

Describe here or attach separate sheet if needed:

**SECTION II - TO BE COMPLETED BY BRANCH CHIEF AND ASSOCIATE DIRECTOR**

	Name (Please Print)	Review	Re-Review (if needed)
8. BRANCH-LEVEL REVIEW	<input type="checkbox"/> Branch Chief: <u>Paul Fearn</u> <input checked="" type="checkbox"/> Delegate: <u>Valentina Petkov</u>  (Branch Chief signature/date required if delegating review)	<input checked="" type="checkbox"/> Approved (minor or no edits; no re-review needed) <input type="checkbox"/> Revisions required, followed by re-review <input type="checkbox"/> Disapproved  Signature of Reviewer/date	<input type="checkbox"/> Approved <input type="checkbox"/> Disapproved  Signature of Reviewer/date
9. PROGRAM-LEVEL REVIEW	<input type="checkbox"/> Associate Director: <u>Lynne Perbatny</u> <input checked="" type="checkbox"/> Delegate: <u>Paul Fearn</u>  (Associate Director signature/date if delegating review)	<input checked="" type="checkbox"/> Approved (minor or no edits; no re-review needed) <input type="checkbox"/> Revisions required, followed by re-review <input type="checkbox"/> Disapproved  Signature of Reviewer/date	<input type="checkbox"/> Approved <input type="checkbox"/> Disapproved  Signature of Reviewer/date
10. OD-LEVEL REVIEW (Senior Staff authors only)	<input type="checkbox"/> Director _____ <input type="checkbox"/> Delegate: _____  Director signature if delegating review	<input type="checkbox"/> Approved (minor or no edits; no re-review needed) <input type="checkbox"/> Revisions required, followed by re-review <input type="checkbox"/> Disapproved  Signature of Reviewer/date	<input type="checkbox"/> Approved <input type="checkbox"/> Disapproved  Signature of Reviewer/date

Handwritten mark or signature.

**Early Detection of circulating tumor material and digital imaging for management of pancreatic cancer**

*Running Title:* Pancreatic cancer detection and diagnosis

Radim Moravec, Rao Divi and Mukesh Verma

Radim Moravec, Surveillance Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, National Institutes of Health, Rockville, MD, 20850 USA

Rao Divi and Mukesh Verma, Methods and Technologies Branch, Division of Cancer Control and Population Sciences, National Cancer Institute, National Institutes of Health, Rockville, MD 20850 USA

*Correspondence to:* Mukesh Verma PhD, Branch Chief, Technology and Methods Branch, Epidemiology and Genomics Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, National Institutes of Health, Rockville, MD 20850 USA. [vermam@mail.nih.gov](mailto:vermam@mail.nih.gov), Telephone: +1-240-276-6889, Fax: +1-240-276-7921

*Author contributions:* RM wrote the paper; RD and MV contributed equally by providing guidance and editorial review.

*Supportive foundations:* Publishing of this manuscript was supported by the Division of Cancer Control and Population Sciences, National Cancer Institute, NIH, Rockville MD, 22805 USA.

*Conflict-of-interest statement:* The authors have no conflicts of interest to report in preparing this work including but not limited to financial, commercial, personal, political, intellectual or religious interests.

*Keyword:* Circulating tumor cells, digital pathology, early detection, exosomes, pancreatic cancer.

*Acknowledgements:* This article is dedicated to Sgt. Mark Diehl.

Format: World Journal of Gastrointestinal Oncology

**Abstract** Pancreatic cancer is a leading cause of cancer-related death worldwide. Clinical symptoms typically present late when treatment options are limited and survival expectancy is very short. Metastatic mutations are heterogeneous and can accumulate up to twenty years before pancreatic cancer diagnosis. Given such genetic diversity, detecting and managing the complex states of disease progression may be limited to imaging modalities and markers present in circulation. Recent developments in digital pathology research show potential for early pancreatic cancer detection, making a differential diagnosis, and predicting treatment sensitivity leading to long-term survival in advanced stage patients. Despite large research efforts, the only serum marker currently approved for clinical use is CA 19-9. Utility of CA 19-9 has been shown to improve when it is used in combination with pancreatic cancer-specific markers. Efforts are being made to develop early screening assays that can detect tumor-derived material, present in circulation, before metastasis takes a significant course. Detection of markers that identify circulating tumor cells and tumor-derived extracellular vesicles in biofluid samples offers a promising non-invasive method for this purpose. Circulating tumor cells exhibit varying expression of epithelial and mesenchymal markers depending on the state of tumor differentiation. This offers a possibility for monitoring disease

progression using minimally invasive procedures. Extracellular vesicles also offer the benefit of detecting molecular cargo of tumor origin and add the potential to detect circulating vesicle markers from tumors that lack invasive properties. This review integrates recent genomic insights of pancreatic cancer progression with developments in digital pathology and early detection of tumor-derived circulating material.

**Core tip** Pancreatic cancer (PC) is a leading cause of cancer-related death. PC mutations accumulate 20 years before patient death with metastatic mutations occurring late in the process. Metastatic risk increases dramatically when tumor diameter is greater than 1 cm. Most PC cases are diagnosed at late metastatic stages when survival is short. Outcomes could be improved if non-invasive methods could detect early stages of the disease and guide treatment decisions. Recent studies indicate this may be possible with application of digital pathology and imaging, screening of CA 19-9 with additional markers, and detecting circulating tumor material in early-stage PC patients.

### ***Introduction***

Pancreatic cancer (PC) is the third leading cause of cancer-related death in men and women in the U.S surpassing breast cancer [1][2]. Projections indicate PC will outpace colorectal cancer and become the second leading cause of cancer-related death in the U.S. by 2020[2]. The majority of pancreatic tumors (90%) are classified as adenocarcinomas arising from the ductal epithelium with an annual incidence of 45220 patients diagnosed with pancreatic ductal adenocarcinoma (PDAC) in the U.S.[3][1]. Estimates suggests that only 1.3-10% of patients diagnosed with pancreatic cancer have familial basis for the disease where a genetic component is inherited from a relative [4]. The remaining majority of PDAC cases display large genomic heterogeneity[5]. Five-year survival is about 25% for localized stages but only 2% for advanced disease [1]. The best curative treatment is surgical resection, if performed early it presents a 5-year survival in 25-30% lymph node negative patients but only 10% for those with positive

lymph nodes<sup>[6][7][8]</sup>. Less than 20% of PC cases are diagnosed early enough for surgical intervention<sup>[2]</sup>. Relapse rate after surgery is typically high (80%) for this type of cancer and surgery is often followed by adjuvant chemotherapy or chemoradiation<sup>[2][9]</sup>. Approximately 80% of PDAC patients are diagnosed late when the disease becomes locally advanced or metastatic, where palliative chemotherapy is the only treatment option<sup>[10]</sup>. Since 1997, Gemcitabine has been commonly used over 5-Fluorouracil (5-FU) albeit with only a modest median Overall Survival (OS) advantage of 5.6 months (Gemcitabine) versus 4.4 months (5-FU) in patients presented with advanced stage<sup>[11]</sup>. Extensive efforts have been made over the past decade, including numerous randomized phase III clinical trials, to evaluate combinatorial drug treatments for patients with advanced disease<sup>[12]</sup>. To date erlotinib, an epidermal growth factor receptor (EGFR) inhibitor, plus gemcitabine is the only course with a targeted therapy agent approved by the U.S. Food and Drug Administration (FDA) for first-line use in advanced pancreatic cancer<sup>[13][14][15]</sup>. FOLFIRINOX and nab-paclitaxel/gemcitabine have recently emerged as a combinatorial treatment with results that may reach the one-year survival barrier <sup>[16][17]</sup>. Great focus has been extended into developing methods for improving early detection of the disease and exploring alternate treatment options that can extend survival in patients with late stage presentation<sup>[14]</sup>. This review provides description of the genomic fingerprints that drive disease progression and discusses selected features relevant to detection and treatment in this biological context. We further highlight recent advances in digital pathology, improvements in CA 19-9 testing, and detection of circulating tumor cells and tumor-derived extracellular vesicles in biofluids of PC subjects. Particular attention is made to literature that provides examples of material isolated from human PC subjects along with cell culture or animal model systems that explore mechanistic underpinnings.

## **Pancreatic Cancer Progression and Genetics**

Computational modeling of primary pancreatic tumors supports the observations that metastatic probability increases exponentially with tumor size<sup>[18][19]</sup>. A patient with a primary tumor size of 1 cm in diameter is predicted to have a 28% probability of harboring metastasis at the time of diagnosis. This dramatically increases to 73% probability with a tumor size of 2 cm and elevates to 94% chance for a tumor size of 3 cm<sup>[19]</sup>. This clearly suggests that systemic treatments that target rapidly growing cells need to be administered early before log-phase growth is reached. For conventional therapies to improve survival, it will become paramount to detect early lesions before significant invasion takes course. The term pancreatic intraepithelial neoplasia (PanIN) was first coined in 1999 to describe ductal lesions which form as precursors to invasive cancer <sup>[20]</sup>. A progression model was soon after proposed where *HER-2/neu* overexpression and *KRAS* mutations are observed early, *p16* (*CDKN2A/INK4a*) gene inactivation occurs at intermediate stages, with inactivation of *p53*, *DPC4*, and *BRCA2* occurring late<sup>[20]</sup>.

Recent evidence suggests that the development from primary tumors to metastatic cancers can take up to two decades, based on genomic sequence comparisons and mathematical analysis. The development of parental clones from an initiated tumor cell is estimated to take an average of 11.7 years, with an additional 6.8 years for expansion of metastatic subclones, and another 2-3 years before tumors disseminate to distant organs leading to patient death<sup>[21]</sup>. The founder mutations present only in the parental clones accumulate in a large number of driver genes involved in tumorigenesis such as *KRAS*, *TP53* and *SMAD4*. The resulting subclones, giving rise to metastatic lesions, contain additional progressor mutations which vary highly among subclones<sup>[21]</sup>. This suggests that distant metastasis occurs late during the genetic evolution of pancreatic cancer. These observations are consistent with findings that show more than 50% of the genomic rearrangements occur early during tumor progression being present in both primary and metastatic clones in the patient<sup>[22]</sup>. If these rearrangements could be narrowed to distinct genes or protein signaling pathways,

they could serve as powerful targets for therapeutics made highly effective by reaching both primary and metastatic sites. In addition to identifying mutation hot-spots in metastatic clones, it will be important to compare founder mutations in primary tumors between patients with different survival outcomes to discover early factors that commit patients to a high risk course<sup>[23]</sup>.

Pancreatic cancers were shown to have gene expression alterations in an average 69 gene sets, half of which cover at least twelve core signaling pathways with functional relevance in 67-100% of observed neoplasias <sup>[24][25]</sup>. Even though these 12 overlapping cascades appear to be genetically altered in majority of the tumors, alterations of the pathway components themselves vary greatly between individual tumors<sup>[24][25]</sup>. This implies that therapies directed against these actionable targets may need to implement multi-targeted approaches based on selected patient subgroups, or consist of cocktails that effectively abolish entire signaling cascades. <sup>[14][26]</sup>.

A recent study performing whole-genome sequencing and copy number variation (CNV) analysis found a total of 857,971 point mutations, insertions and deletions in 100 samples of PDAC<sup>[27]</sup>. The four most commonly mutated genes observed in PDAC patients are the oncogene *KRAS* (75-90%), tumor suppressor genes *TP53* (74%), *CDKN2A/p16* (35%), and *SMAD4* (31%), along with inactivating mutations in the Rac exchange factor *PREX2*, the tumor suppressor *RNF43*, and the histone demethylase *KDM6A* observed in 10-18% of subjects <sup>[27]</sup>. Focal amplification of druggable oncogenes such as *ERBB2*, *MET*, *FGFR1*, *CDK6*, *PIK3R3* and *PIK3CA* is observed at very low prevalence among only 1-2% of patients<sup>[27]</sup>. Levels of protein expression or activity were not determined in these studies, however, to understand the functional significance of the focal amplifications. Integrated genomic analysis of PDAC identified 32 mutated genes that comprise 10 signaling pathways: *KRAS*, TGF-beta, WNT, NOTCH, ROBO/SLIT signaling, G1/S transition, SWI-SNF, chromatin modification, DNA repair and RNA processing<sup>[28]</sup>. Four tumor subtypes were

identified based on differential expression of transcription factors and downstream targets: squamous, pancreatic progenitor, immunogenic, and aberrantly differentiated endocrine exocrine (ADEX) tumors. These tumor subtypes were sorted by gene programs to identify genetic factors that impact OS in PDAC subjects<sup>[28]</sup>.

PDAC primary tumors can also be sorted into three distinct subtypes based on gene expression patterns and drug sensitivity: classic, quasimesenchymal and exocrine-like<sup>[29]</sup>. The classic subtype, more sensitive to the EGFR inhibitor erlotinib, expresses high levels of adhesion-associated epithelial genes such as *AGR2*, *S100PBP* and *GATA6*. The quasimesenchymal subtype is more sensitive to gemcitabine and expresses high levels of mesenchymal genes such as *TWIST1* and *S100A2*. The exocrine-like subtype has high expression of tumor cell derived digestive enzyme genes such as *REG3A* and *PRSS1*<sup>[29]</sup>. These findings open the possibility for stratifying patients based on tumor gene expression patterns as a means for predicting drug sensitivity.

Taken together, these observations demonstrate that primary and metastatic tumors of the pancreas are highly heterogeneous and contain several distinct clonal populations with unique molecular signatures which develop over a long period of time. This makes targeted therapy difficult, unless common pathways are found that can be effectively blocked by personalized drug regimens <sup>[5]</sup>.

## **The Pancreatic Stroma**

Another source of genetic diversity can be found within the pancreatic stroma. PDAC cells are surrounded by a rich stroma that is typically far more abundant in cell types other than the tumor. Pancreatic stroma contains a variety of cells including stellate cells, immune cells, fibroblasts, vascular endothelial cells and the extracellular matrix which make up the tumor micro-environment (TME)<sup>[30]</sup>. TME plays a pivotal role in tumor behavior including proliferation, drug resistance, invasion and localized immune response<sup>[30][31]</sup>. A clinical study investigating intraoperative gemcitabine

infusions during PDAC resection showed that high stromal density inhibits hENT1-mediated drug incorporation into the tumor [32][33]. Investigators in this study derived mass transport parameter (MTP) cutoff values based on expression of the nucleoside transporter hENT1 in the tumor, and pancreatic stromal density scores calculated from CT scans[32]. Applying MTP cutoffs to a cohort of 110 patients, who received gemcitabine therapy, revealed a 5-year survival rate of 40% in subjects with favorable transport parameters compared to a 15% survival rate in subjects who did not reach the parameter cutoff point[32]. This study demonstrates that stromal density and drug transport properties can be measured during surgery, using routine contrast-enhanced CT scans and immunohistochemistry, as a highly effective means for predicting significant response to cancer therapy. hENT1 expression in tumor cells permits bidirectional transport of pyrimidine nucleosides such as gemcitabine, capecitabine and 5-FU[34]. High expression of hENT1 in PC patients treated with gemcitabine is predictive of improved survival[33][35][36]. These studies open the possibility for determining drug sensitivity in resected patients through screening morphological features of the stroma combined with assessment of pharmacogenomic profiles[37].

The pancreatic stroma is enriched with large diversity of constituents, making it difficult to score clinically. A recent study applied a blind source separation technique called non-negative matrix factorization (NMF) to analyze gene expression from a microarray dataset that included 145 primary and 61 metastatic PDAC tumors in comparison to 134 normal tissue samples[38]. This technique effectively generated gene expression signatures sorted by tumor, stromal and normal cellularity. Patients that were identified with a “classical” tumor subtype had a median survival of 19 months compared to patients with a “basal-like” tumor subtype that demonstrated a significantly worse survival of 11 months. Additionally, two stromal subtypes were identified in patients: a “normal” subtype with 24 months-median survival and an “activated” subtype with significantly worse median survival of 15 months. These

techniques lead the way for identifying genetic markers that may otherwise be obscured by material from confounding normal and stromal tissue<sup>[38]</sup>.

Mounting evidence supports the hypothesis that pancreatic tumor micro-environments play a significant role in pathological outcome and treatment response and should therefore be clinically evaluated as a standard practice. The use of digital imaging combined with pharmacogenomic analysis could extend the application of existing treatments for personalized medicine. Best clinical outcomes come from early diagnosis of the disease. Leveraging the biological properties of pancreatic adenocarcinomas and their surrounding micro-environment for early detection and diagnosis would provide maximum benefit for patient survival.

### *Current Diagnostic Methods using Serum*

Presently, there are no suitable pancreatic cancer screening strategies effective for early detection of PC in the general population. Diagnosis of pancreatic ductal adenocarcinoma is made by pathological assessment of a tissue biopsy. The current gold standard is via an endoscopic ultrasound technique coupled with fine needle aspirations (EUS-FNA) which has a sensitivity of 75-94% and specificity of 78-95%<sup>[8][39]</sup>. For patients who have non-diagnostic FNAs or cannot undergo endoscopy, treatment decisions are based on imaging or determining CA 19-9 serum levels<sup>[8]</sup>. The only serum biomarker approved by the FDA for pancreatic cancer is the sialylated Lewis (a) blood group antigen CA 19-9 which is not tumor specific and is frequently elevated during many malignancies, pancreatitis, cholangitis, obstructive jaundice, hepatobiliary cancer, and benign biliary obstruction <sup>[40][41]</sup>. CA 19-9 alone has not been shown to be effective as a screening marker for PDAC among the general population based on most studies <sup>[42]</sup>. However, sensitivity (60-70%) and specificity (70-85%) of CA 19-9 improve significantly in patient cohorts presented with pancreatobiliary disease<sup>[42][43]</sup>. Low serum CA 19-9 levels following surgery correlate with improved survival <sup>[42]</sup>. Oncologists occasionally use CA 19-9 to track response to chemotherapy but the

predictive significance of CA 19-9 for this purpose has reported some variability<sup>[40][42][44]</sup>.

Measuring CA 19-9 in combination with other markers such as CEA, CA242, and TIMP1, however was shown to improve its predictive value<sup>[42][45][46]</sup>. Brand et al. could identify PDAC patients using two independent panels: CA 19-9, CEA, and TIMP-1; and a second panel containing CA 19-9, ICAM-1, and OPG<sup>[46]</sup>. Both panels demonstrated increased sensitivity and specificity over CA 19-9 alone (Table 1)<sup>[46]</sup>. Recently, O'Brien et al. discovered CA 19-9 (>37 U/ml) and CA 125 (>30 U/ml) serum levels can be elevated up to two years before PDAC diagnosis based on a nested case control study<sup>[41]</sup>. CA 125 has been reported to distinguish malignant from benign PC tumors with 60.8% sensitivity and 83.3% specificity which improved to 87.8% and 77.8% respectively when combined with CA 19-9<sup>[47]</sup>. PAM4, an antibody which binds mucin MUC1 and MUC5AC epitopes expressed in pancreatic cancer, was capable of identifying 64% of stage I PDAC patients with high discriminatory power compared to those with benign pancreatic disease<sup>[48]</sup>. PAM4 is capable of distinguishing normal pancreas from PanIN-1A, PanIN-1B, PanIN-2, and PanIN-3 lesions, intraductal papillary mucinous neoplasia (IPMN) lesions, as well pancreatic adenocarcinomas of various grades<sup>[49]</sup>. Combining CA 19-9 with PAM4-reactive marker improved sensitivity (84%) without a loss in specificity (82%) in a serum-based enzyme immunoassay (EIS)<sup>[48]</sup>. Despite some propensities for false positivity, CA 19-9 continues to be a benchmark serum marker for evaluating PC in the clinical setting. It will be important to test combinations of other markers in addition to CA 19-9 to improve its diagnostic utility.

### ***Tumor Imaging and Digital Pathology***

In addition to biopsies and serum marker tests, lesions and primary tumors can be characterized by clinical imaging. Computed tomography (CT) and magnetic resonance imaging (MRI) are the most frequently used imaging method for diagnosis

and clinical staging <sup>[30][40]</sup>. Additional screening approaches using imaging multimodalities include endoscopic ultrasonography (EUS), magnetic resonance cholangiopancreatography (MRCP), and endoscopic retrograde cholangiopancreatography (ERCP)<sup>[4]</sup>. However, these approaches are limited to surveillance centers with robust pancreatic cancer programs and are typically only performed on high-risk patients.<sup>[50][51]</sup> MRI and EUS have been proposed for use as first line modalities but often fail to distinguish benign from malignant lesions<sup>[52]</sup>. Emerging imaging modalities and molecularly targeted imaging agents are of great interest as early detection strategies but they may be cost prohibitive and inaccessible to many patients.<sup>[53]</sup>

Upon diagnosis, patients are staged based on the AJCC 7<sup>th</sup> Edition Staging Manual criteria before proceeding to surgery<sup>[8][54]</sup>. This is typically accomplished through cross-sectional imaging (CT or MRI) along with tissue biopsy<sup>[8]</sup>. Among those staged with resectable disease by biopsy, only 70-85% actually present with resectable tumors, intraoperatively<sup>[8]</sup>. This indicates a need for improvements in staging methodology which may be enhanced by digital pathology<sup>[8]</sup>. The field of digital pathology has recently grown to complement histological diagnosis performed by pathologists<sup>[55]</sup>. These methods extract and quantify histological features from whole slide images thus improving on the subjective nature of the work<sup>[56]</sup>.

Langer et al. developed a method that can accurately predict early pancreatic lesions with a 93% success rate in an independent test set using tissue obtained from mouse models of early-stage PDAC<sup>[57]</sup>. The program uses a top-down object learning paradigm similar to the methodology used by human pathologists. Initially, ducts, nuclei and tumor stroma are identified and segmented. From those, secondary morphological features such as duct deformation and nuclei malformations are measured. These data sets are then used to train a predictive model that distinguishes normal tissue from premalignant cancer lesions<sup>[57]</sup>. Similar techniques can be extended

to accomplish classification of PDAC by grade using human tissue samples<sup>[58]</sup>. Diagnosis of PDAC was made based on three parts: segmentation and feature extraction; model learning and validation; and diagnosis. Training data measuring ducts, consisting of the lumen and epithelial nuclei, can distinguish normal human subjects and those with grade I and grade II PDAC with an accuracy of 94%<sup>[58]</sup>. Automated systems have been developed for making a differential diagnosis of rare lesions such as cystic neoplasms of the pancreas using human biopsy tissue<sup>[59]</sup>. Song et al. were able to distinguish benign serous from malignant mucinous cystadenomas using a computer-aided design technique<sup>[59]</sup>. Cystic regions were identified and epithelial cells surrounding the lumen were discerned. Three classes of features were analyzed by the program to achieve a differential diagnosis: the number and size of cysts, characteristics of the surrounding epithelium, and indication of mucus production<sup>[59]</sup>.

Current applications of digital pathology for pancreatic cancer do not offer much more beyond histological diagnosis performed by a pathologist but indicate potential for detecting early lesions. Improvements could be made, for example, by developing digital pathology methods for images annotated with clinical data from population-based repositories. This could potentially aid the discovery of morphological features associated with treatment and survival outcomes.

The intended goal beyond research is to incorporate digital tools into clinical practice as a way to standardize histological diagnosis in patients at high risk of developing the disease. This could improve staging and determination of resectability. Some concerns raised include public health consequences if misdiagnosis is caused by improper use or analysis of poor quality images<sup>[60]</sup>. The Food and Drug Administration recently released a guidance for technical performance assessment of digital pathology whole slide imaging (WSI) devices<sup>[61]</sup>. Currently, WSI devices are classified as Class II for methods that provide adjunct analysis after a primary diagnosis is made using glass

slides. WSI devices which make a primary diagnosis are classified as high-risk Class III devices if their intended use is new and lacks a Class II predicate. A *de novo* process provides a less resource-intensive approval path to Class I/II classification if special controls are presented that provide reasonable assurance of safety and effectiveness. A more clearly-defined approval process for manufactures would enhance innovation potential and commercialization of digital pathology instruments and software<sup>[62]</sup>.

### ***Detecting Tumor Cells in Circulation***

Performing invasive biopsies for routine screening of the general population is not reasonably a feasible option. Detecting tumor material in the blood or other biofluids would be ideal for many reasons. A test assessing a panel of markers in biofluids could be ordered by physicians in most clinical centers, and collected by non-invasive or minimally invasive procedures. Performing additional tests using the same starting material could easily lead to diagnostic refinement. The diagnostic source can be expanded to include non-tumor biologics such as components of the immune system, blood/serum, pancreatic juice, stool, oral and gut microbiota, and markers of metabolic activity. Given patient variability, measuring systemic profiles of markers not directly derived from tumors may not yield the specificity and sensitivity necessary to accurately determine risk for developing advanced pancreatic cancer. A search for “pancreatic cancer” in the published literature can easily generate over 50,000 returns which documented more than 2500 individual genes as potential PC biomarkers due to their overexpression patterns <sup>[63]</sup>. A compendium of PC biomarkers identified at least 1000 molecules with evidence of upregulation in precursor lesions<sup>[63]</sup>. Early detection of these precursor lesions particularly before invasive cells establish colonization would be ideal.

A critical study, using genetically engineered mouse models of PanIN, showed that cells from preneoplastic lesions can breach the basement membrane and spread into the stroma <sup>[64]</sup>. Contrary to conventional wisdom, these cells undergo epithelial-to-

mesenchymal transition (EMT) and enter the blood into circulation with no evidence of carcinoma. These findings suggest that EMT transition can occur as an early phenomenon even before histologic emergence of cancer. These cells acquire a mesenchymal phenotype, exhibit stem cell properties, have tumor-initiating capacity, and are most abundantly observed at inflammatory foci<sup>[64]</sup>. Induction of pancreatitis and immunosuppressive treatment with dexamethasone have strong effects on dissemination supporting a link between early precursor cell invasion and localized inflammation <sup>[64]</sup>. Typical circulating tumor cell (CTC) markers such as EpCAM are expressed in less than 20% of the PanINs in this model system<sup>[64]</sup>. This has implications for commercial methods which may overlook these circulating precursors, because they rely on such epithelial markers for CTC detection.

EMT in primary cells was shown to be associated with acquisition of stem cell-like characteristics<sup>[65]</sup>. Both normal and cancer stem cells possess the ability to self-renew and produce differentiated progeny<sup>[26]</sup>. Cancer stem cells are further functionally defined by having enhanced tumor initiating capacity when transplanted to a permissive host<sup>[64]</sup>. *In vivo*, CTCs detach from the primary tumor and enter the blood where they can be transported to distant sites with only 0.01% surviving to form metastases<sup>[66]</sup>. CTC detection has been extensively used for prognosis (progression free survival and overall survival) and predicting response to treatment in breast, prostate, colorectal and lung cancers<sup>[67][68][69][70][71]</sup>. CTCs have also been detected in pancreatic cancer patient samples but their prognostic potential remains to be optimized outside the limitations of a small sample of subjects <sup>[66][72][73][74]</sup>.

Because circulating tumor cells are present at very low concentrations in the blood, typically one CTC per billion blood cells, CTCs need to be enriched, to differentiate them from the vast hematopoietic cell background, and characterized to verify their tumor origin <sup>[66]</sup>. Several enrichment media for density-gradient centrifugation are commercially available including LymphoPrep™ (Axis-Shield),

Ficoll-HyPaque™ (Sigma-Aldrich), Oncoquick<sup>R</sup> (Greiner Bio-One), and RosetteSep™ Human Circulating Epithelial Tumor Cell Cocktail with SepMate™ (StemCell Technologies). Enrichment is typically followed by targeted isolation. Four strategies are available to isolate and capture CTCs: positive selection using antibodies attached to solid-support, negative selection, cell size-based methods such as filtration, and physical property-based methods [74]. Most CTC detection methods rely on either positive immunoselection of cells expressing the epithelial cell adhesion molecule (EpCAM) or negative selection by depleting leukocytes from the blood using CD45-binding antibodies [75]. Commercial immunomagnetic bead separation systems are available including EasySep cell separation (StemCell Technologies), Dynabeads (Invitrogen), CellSearch CTC system (Janssen Diagnostics) and MACS (Miltenyi). CellSearch CTC is the only system approved by the FDA for capturing and enumerating CTCs of epithelial origin by CD45-, EpCAM+ and cytokeratin+ selection [76]. CellSearch has been cleared by the FDA for management of breast, colorectal and prostate cancers and has also been tested in PDAC patients with detection rates varying from 11-45% [41][75][77][78][79][80][81][82].

Once isolated, circulating tumor cells are typically characterized by immunocytochemical (ICC) staining or nested real-time polymerase chain reaction (RT-PCR). Detection strategies typically assess epithelial mRNA profiles which include *EpCAM*, epithelial carcinoembryonic antigen (*CEA*), *CEACAM5*, *CK19*, *BIRC5* and *MUC1*[73]. There are currently more than 40 assay platforms for CTC detection and enrichment that have been widely publicized[83]. Among these, the utilization of microfluidics and microarray technology in CTC detection is expanding.

CTC detection was investigated as a prognostic tool in a LAP07 international multicenter randomized study to assess if patients with locally advanced pancreatic carcinoma (LAPC) would benefit from chemoradiotherapy over continuation of chemotherapy[78]. Bidard et al. were able to achieve a CTC detection rate of 11% using

a low cut-off of one or more CTCs/7.5 ml of blood using the CellSearch system<sup>[78]</sup>. This is lower than the 50% detection rate typically reported for metastatic PC patients<sup>[81]</sup>. CTC positivity nonetheless was a prognostic factor for overall survival which was lower in CTC positive LAPC patients<sup>[78]</sup>. More CTCs can be detected in the blood of PC patients using ISET (Isolation by Size of Tumor Cell) based on a comparative study which found detection of 26 CTCs/7.5 ml blood using ISET compared to 2 CTCs/7.5 ml blood by CellSearch<sup>[79]</sup>. ISET also detected CTCs in a much higher proportion of patients (93%) versus CellSearch (40%)<sup>[79]</sup>. ISET is a filtration-based, marker-independent method that sorts by cell size and morphology using filter modules offered by a company started by the inventor of the technology (Rarecells Diagnostics) <sup>[84][85]</sup>. Thus ISET may offer a significant advantage over CellSearch which relies on expression of EpCAM for CTC identification. PDAC cells, among carcinomas, are more prone to epithelial-mesenchymal transition (EMT) which reduces the expression of EpCAM<sup>[75][86][87]</sup>. This presents a problem for PC detection using CTCs as most of the current CTC detection methods rely on EpCAM or other epithelial molecules for CTC detection<sup>[66][83]</sup>.

There exists a critical need for the development of assays that can additionally identify CTCs which undergo EMT and lose expression of typical epithelial surface antigens. Ren et al. detected CTCs in peripheral blood of advanced stage PC patients before (in 80% of patients) and after treatment (in 29% of patients) with 5-fluorouracil (5-FU) by immunostaining for CA19-9 and CK8/18 expression<sup>[88]</sup>. The mean concentration of blood CTC decreased from 16.8 cells/7.5 ml of blood before chemotherapy to 3.8 cells/7.5 ml blood after a seven-day cycle of 5-FU chemotherapy<sup>[88]</sup>. Evidence of apoptosis induced by 5-FU was observed in CTCs obtained from patients and in pancreatic cell line models (PL45 and PANC-1 cells)<sup>[88]</sup>. These studies open the possibility for using CTC assays to monitor chemotherapy efficacy and extent of remission although they fail to selectively identify mesenchymal antigens expressed by CTCs. Other potential mesenchymal protein marker

candidates include Cadherin 2, Vimentin, Snail Slug, zinc finger E-box binding homeobox1 (ZEB1), and Twist family basic helix-loop-helix transcription factor 1 (TWIST1)<sup>[76]</sup>. These mesenchymal markers could be combined with PC-specific markers to increase specificity.

To verify tumor origin, isolated CTCs can also be screened for genes expressed or mutated predominantly in PC such as *KRAS*. Court et al. detected *KRAS* mutations in 92% of pancreatic cancer patients using a NanoVelcro/laser capture microdissection (LCM) platform<sup>[89]</sup>. This technique captures CTCs on a microfluidic chip using biotinylated anti-EpCAM antibodies and is followed by identification through ICC staining of CD45, CEA, and staining of pancytokeratin for nuclear morphology. Mutations in *KRAS* were not observed in white blood cells and overall reliability of the assay required isolation of only 10-100 circulating tumor cells<sup>[89]</sup>. Chausovsky et al. detected the expression of Cytokeratin 20 (*CK20*) in 22/28 PC patients using RT-PCR analysis of peripheral blood CTCs<sup>[90]</sup>. Soeth et al. found that *CK20* was expressed in CTCs of 33% of patients in a larger cohort (n=154) who had significantly shorter overall survival<sup>[91]</sup>. Cytokeratin 7 (*CK7*) and cytokeratin 20 (*CK20*) are expressed in a variety of epithelial neoplasms including majority of pancreatic carcinomas (62%)<sup>[92]</sup>. A variety of commercial platforms are now available for detection of amplified CTC DNA such as TruSeq Amplicon (Illumina) and Ion Torrent AmpliSeq™ (Life Technologies).

Levels of RNA expression can also be measured by RT-PCR or directly imaged by *in situ* RNA hybridization using platforms such as ViewRNA™ CTC Platform (Affymetrix). Zhou et al. measured mRNA expression of *h-TERT*, *C-MET*, *CK20*, and *CEA* by RT-PCR in CTCs isolated by immuno-magnetic enrichment using EpCAM<sup>[93]</sup>. This method can distinguish PC patients from benign control subjects with high degree of specificity. Further, when pancreatic patients were in later stages, the expression rate for *C-MET* (67%), *CK20* (75%) and *CEA* (75%) were statistically higher than during earlier stages<sup>[93]</sup>. These findings open the utility of CTC detection for monitoring

Epidermal Growth Factor Receptor (EGFR) is a receptor tyrosine kinase (RTK) activated in a subset of pancreatic cancer cells [113]. Adamczyk et al. found pancreatic cell lines (BxPC3, MiaPaca2, Panc1, Paca44 and A818-4 cells) secrete a 110 kDa soluble form of the EGFR ligand-binding extracellular domain (sEGFR) directly into conditioned media<sup>[114]</sup>. A 170kDa intact receptor and a 65 kDa processed form, including the intracellular kinase domain, are secreted as constituents of exosomes. Exosomes were separated from the secretome by ultracentrifugation and confirmed by exosome markers Alix, CD9, CD63 and Syntenin. The full-length EGFR was enriched 20-fold in exosomes along with 1600 other proteins found in the fraction by mass spectrometry [114]. The reason for compartmentalized release of these processed EGFR forms is currently not known. Soluble EGFR may provide a method for distant receptor transactivation or may confer EGFR positivity in cancer cells lacking EGFR expression. EGFR+ exosomes may also enhance drug resistance by serving as a decoy for therapeutic antibodies. This has been observed in HER2+ exosomes secreted by breast cancer cells that were shown to inhibit cell proliferation effects of Trastuzumab but not Lapatinib [115]. The next important step will be detecting EGFR+ exosome in healthy and PC patients. Whether these isoforms possess any oncogenic mutations also needs to be explored before clinical use of these exosomes as cancer-specific biomarkers is considered.

*KRAS* is an oncogene that is mutated in 90% of pancreatic cancer cases<sup>[116][117]</sup>. Kahlert et al. isolated large (>10- kb) double stranded genomic DNA fragments from EVs originating from pancreatic cancer cell lines and from serum of PDAC patients<sup>[118]</sup>. Exosomes were purified from cell lines (Panc-1, T3M-4) and serum isolated from patients prior to surgical resection using ultracentrifugation after filtration. Exosomes were further verified by expression of CD9, TSG101, and CD63 by FACS analysis. By using whole genome sequencing, the authors demonstrated that PDAC serum exosomes contain not just mutated *KRAS* and *p53* oncogenes but also genomic DNA fragments spanning all chromosomes [118]. This suggests that genomic fragments can

be isolated from purified PC exosomes and sequenced for analysis. Exosomes isolated from peripheral blood and pleural effusions can be sequenced to profile the genomes and transcriptomes of patients with pancreaticobiliary cancers<sup>[119]</sup>. Traditional tissue biopsies for these deeply located visceral cancers are difficult to safely acquire in less specialized clinical centers. These studies create the possibility of performing genomic panel tests to identify oncogenic material from exosomes isolated from patients suspected of having elevated risk of PC or those where traditional biopsies are not feasible to obtain.

In addition to carrying genomic DNA, exosomes can also directly inhibit translation or target mRNA for degradation through the delivery of microRNA<sup>[120]</sup>. Exosomal miR-21, miR-212-3p and miR-203 and have been shown to enhance chronic pancreatitis, modulate immune response, and induce drug resistance<sup>[120][121][122]</sup>. Que et al. found elevated levels of miR-17-5p, which correlate with metastatic stage, in serum exosomes of PC patients compared to healthy controls <sup>[123]</sup>. Levels of exosomal miR-21 were also higher in PC patients versus healthy and chronic pancreatitis group but did not correlate with PC differentiation or stage<sup>[123]</sup>. The concentration of EVs in serum or plasma is almost one thousand times higher than in urine, a less invasive biofluid where exosomes remain stable at room temperatures for up to a week <sup>[110]</sup>. Ymir Genomics has developed a novel precipitation reagent, Ymirite, which isolates extracellular nucleic acids and vesicles from urine samples. Exiqon offers two exosome enrichment kits (miRCURY) for serum/plasma and urine isolation and a qPCR detection system (LNA™) for miRNA detection which enables profiling of biofluids where microRNA levels are extremely low. Further improvements in exosome and oncosome cargo characterization will significantly improve the clinical prospects of EVs.

### ***Exosomal Markers That Indicate Pathogenic Effects of PDAC***

Once released into circulation, the destination of tumor-secreted exosomes can be directed through expression of membrane proteins that guide cellular targeting such as integrins, tetraspanins, phosphatidylserine receptors and heparin sulfate proteoglycans [124][125][126][112]. These features enable exosomes to reach distant sites where they can exert pathogenic effects secondary to the primary cancer. For example, PDAC derived exosomes have been shown to promote liver metastasis through expression of macrophage migration inhibitory factor (MIF) which induces a fibrotic microenvironment when taken up by liver resident Kupffer cells [127][107]. PDAC derived exosomes can also secrete TGF-beta which activates hepatic stellate cells to secrete fibronectin which in turn arrests bone-marrow derived macrophages and neutrophils to produce pro-tumorigenic cytokines in the liver[122][127].

Diabetes is a risk factor for pancreatic cancer but the association is complex[128]. Studies by Javeed et al. suggest that adrenomedullin (AM), secreted into circulation by pancreatic exosomes, reaches remote pancreatic beta cells to induce beta-cell dysfunction by inhibiting insulin secretion[129]. The authors showed AM<sup>+</sup> exosomes, isolated by differential centrifugation, are secreted into cultured media by PC patient-derived primary cell lines as well as into portal/peripheral venous blood of PC patients. Additionally, these AM<sup>+</sup> exosomes also contain CA19-9 making them an attractive pancreatic cancer biomarker [129]. Another PDAC-exosomal protein Bip, also impairs insulin secretion through interactions with pro-insulin [122]. These studies hold promise for potential diagnostic methods which may predict secondary complications to pancreatic cancer.

Detection of exosomes and their cargo presents some attractive qualities as a liquid biopsy technique. Advantages include the ability to capture tumor-derived material circulating before and during metastatic colonization, enable monitoring of treatment effectiveness and recurrence, enhance prognostic capability based on classifying molecular signatures, and serving to indicate secondary complications.

Vesicle enrichment methods have been streamlined and standardized through the availability of commercial kits. The discovery of highly cancer-specific exosomal markers such as GPC1 will provide a foundation that could serve as the basis for accurate and non-invasive diagnostic tests.

### *Concluding Paragraph*

The genetic evolution of pancreatic cancer is complex and may take up to two decades with metastatic mutations occurring relatively late in the process. Diagnosis is made at late stage where large genetic heterogeneity is observed within the tumor. With genotyping costs decreasing it may be possible to predict drug sensitivity following resection through a combination of genomic profiling of the tumor, stromal density image processing and transporter expression determination. Digital analysis of the stroma from CT images has demonstrated the ability to predict a significant survival benefit extending five years after diagnosis for patients who undergo gemcitabine treatment. These methods pave the way for future applications in digital pathology as a means to increase prognostic potential and augment treatment decisions for personalized medicine.

While there is some room for refining existing treatment options to extend survival of late-stage PC patients, early detection of the disease will be paramount to significantly decrease the burden on the population. Detecting physiologically relevant markers in exosomes and circulating tumor cells offers an advantage of testing with little or no discomfort to the patient. This creates the possibility to obtain serial samples of body fluids over time to allow monitoring of disease progression while eliminating risks associated with invasive biopsies. Combining information gained from these two types of tests could potentially increase diagnostic potential during early stages of pancreatic cancer development.

## REFERENCES

1. Siegel RL, Miller KD, Jemal A. Cancer Statistics , 2015. 2015;**65**:5–29 [DOI: 10.3322/caac.21254.]
2. Pancreatic Cancer Action Network. PANCREATIC CANCER FACTS 2016 [Internet]. 2016;Available from: <https://www.pancan.org/wp-content/uploads/2016/02/2016-GAA-PC-Facts.pdf>
3. Fesinmeyer MD, Austin MA, Li CI, Roos AJ De, Bowen DJ. Differences in Survival by Histologic Type of Pancreatic Cancer. 2005;**14**:1766–74
4. Bartsch DK, Gress TM, Langer P. Familial pancreatic cancer — current knowledge. 2012;**9** [DOI: 10.1038/nrgastro.2012.111]
5. Costello E, Greenhalf W, John P. New biomarkers and targets in pancreatic cancer and their application to treatment. *Nat Rev Gastroenterol Hepatol* 2012;**9**:435–44 [DOI: 10.1038/nrgastro.2012.119]
6. Hidalgo M. Pancreatic Cancer. *N Engl J Med* 2010;**362**:1605–17
7. Howlader N, Noone A, Krapcho M, Garshell J, Miller D, Altekruse S, Kosary C, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis D, Chen H, Feuer E, Cronin K. SEER Cancer Statistics Review, 1975-2011, National Cancer Institute. Bethesda, MD [Internet]. based Novemb. 2013 SEER data Submiss. Available from: [http://seer.cancer.gov/csr/1975\\_2011/](http://seer.cancer.gov/csr/1975_2011/)
8. Court CM, Ankeny JS, Hou S, Tseng H, Tomlinson JS. Improving pancreatic cancer diagnosis using circulating tumor cells: prospects for staging and single-cell analysis. *Expert Rev Mol Diagn* 2015;**15**:1491–504 [DOI: 10.1586/14737159.2015.1091311.Improving]
9. Krempien R, Muentner MW, Harms W, Debus J. Neoadjuvant chemoradiation in

- patients with pancreatic adenocarcinoma. *HPB* 2006;**8**:22-8 [PMID: 18333234 DOI: 10.1080/13651820500468034]
10. Herreros-Villanueva M, Gironella M, Castells A, Bujanda L. Molecular markers in pancreatic cancer diagnosis. *Clin Chim Acta* 2013;**418**:22-9 [DOI: 10.1016/j.cca.2012.12.025]
  11. Burris HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Hoff DD Von. Improvements in Survival and Clinical Benefit With Gemcitabine as First-Line Therapy for Patients With Advanced Pancreas Cancer : A Randomized Trial. 1997;**15**:2403-13
  12. Sjoquist KM, Chin VT, Chantrill LA, O'Connor C, Hemmings C, Chang DK. Personalising pancreas cancer treatment: When tissue is the issue. *World J Gastroenterol* [Internet] 2014;**20**:7849-63 [DOI: 10.3748/wjg.v20.i24.7849] Available from: <http://www.wjgnet.com/1007-9327/full/v20/i24/7849.htm>
  13. Yang Z, Yuan J, Di M, Zheng D, Chen J, Ding H, Wu Y, Huang Y, Mao C, Tang J. Gemcitabine Plus Erlotinib for Advanced Pancreatic Cancer : A Systematic Review with Meta-Analysis. *PLoS Med* 2013;**8**:1-10 [DOI: 10.1371/journal.pone.0057528]
  14. Di Marco M, Grassi E, Durante S, Vecchiarelli S, Palloni A, Macchini M, Casadei R, Ricci C, Panzacchi R, Santini D, Biasco G, Marco M Di, Grassi E, Durante S, Palloni A, Macchini M, Biasco G. State of the art biological therapies in pancreatic cancer. *World J Gastroenterol* 2016;**8**:55-66 [DOI: 10.4251/wjgo.v8.i1.55]
  15. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, Campos D, Lim R, Ding K, Clark G, Voskoglou-nomikos T, Ptasynski M, Parulekar W. Erlotinib Plus Gemcitabine Compared With

- Gemcitabine Alone in Patients With Advanced Pancreatic Cancer : A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group. *J Clin Oncol* 2007;**25**:1960–6 [DOI: 10.1200/JCO.2006.07.9525]
16. Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, Adenis A, Raoul J-L, Gourgou-Bourgade S, Fouchardièrre C De, Assenat E, Chauffert B, Michel P, Montoto-Grillot C, Ducreux M. FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer. *N Engl J Med* 2011;**364**:1817–25
  17. Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, Harris M, Reni M, Dowden S, Laheru D, Bahary N, Ramanathan RK, Tabernero J, Hidalgo M, Goldstein D, Van Cutsem E, Wei X, Iglesias J, Renschler MF. Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine. *N Engl J Med* 2013;**369**:1691–703 [DOI: 10.1056/NEJMoa1304369]
  18. Fortner JG, Klimstra DS, Senie RT, Maclean BJ. Tumor size is the primary prognosticator for pancreatic cancer after regional pancreatectomy. *Ann Surg* 1996;**223**:147–53 [PMID: 8597508 DOI: 10.1097/00000658-199602000-00006]
  19. Haeno H, Gonen M, Davis MB, Herman JM, Iacobuzio-Donahue CA, Michor F. Computational modeling of pancreatic cancer reveals kinetics of metastasis suggesting optimum treatment strategies. *Cell* 2012;**148**:362–75 [DOI: 10.1016/j.cell.2011.11.060.Computational]
  20. Hruban RH, Goggins M, Parsons J, Kern SE. Progression Model for Pancreatic Cancer. *Clin Cancer Res* 2000;**6**:2969–72
  21. Yachida S, Jones S, Bozic I, Antal T, Leary R, Fu B, Kamiyama M, Hruban RH, Eshleman JR, Nowak MA, Velculescu VE, Kinzler KW, Vogelstein B, Iacobuzio-Donahue CA. Distant metastasis occurs late during the genetic evolution of

- pancreatic cancer. *Nature* 2010;**467**:1114–7 [PMID: 20981102 DOI: 10.1038/nature09515]
22. Campbell PJ, Yachida S, Mudie LJ, Stephens PJ, Pleasance ED, Stebbings LA, Morsberger LA, Latimer C, McLaren S, Lin M, McBride DJ, Varela I, Nik-zainal SA, Leroy C, Jia M, Menzies A, Butler AP, Teague JW, Griffin CA, Burton J, Swerdlow H, Quail MA, Stratton MR, Iacobuzio-donahue C, Futreal PA. The patterns and dynamics of genomic instability in metastatic pancreatic cancer. *Nature* 2010;**467**:1109–13 [DOI: 10.1038/nature09460]
  23. Dal Molin M, Zhang M, De Wilde RF, Ottenhof NA, Rezaee N, Wolfgang CL, Blackford A, Vogelstein B, Kinzler KW, Papadopoulos N, Hruban RH, Maitra A, Wood LD. Very long-term survival following resection for pancreatic cancer is not explained by commonly mutated genes: results of whole-exome sequencing analysis. *Clin Cancer Res* 2015;**21**:1944–50 [PMID: 24655651 DOI: 10.1016/j.molmed.2014.11.008.Mitochondria]
  24. Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Jimeno A, Hong S, Fu B, Lin M, Eric S, Kamiyama M, Walter K, Nikolskaya T, Nikolsky Y, Hartigan J, Smith DR, Hidalgo M, Leach SD, Alison P, Jaffee EM, Goggins M, Maitra A, Iacobuzio- C, Eshleman JR, Kern SE, Hruban RH, Papadopoulos N, Parmigiani G, Vogelstein B, Victor E, Kinzler KW. Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses. *Science (80- )* 2008;**321**:1801–6 [DOI: 10.1126/science.1164368.]
  25. Takai E, Yachida S. Genomic alterations in pancreatic cancer and their relevance to therapy. *World J Gastrointest Oncol* 2015;**7**:250–8 [PMID: 26483879 DOI: 10.4251/wjgo.v7.i10.250]
  26. Philip PA, Mooney M, Jaffe D, Eckhardt G, Moore M, Meropol N, Emens L, O'Reilly E, Korc M, Ellis L, Benedetti J, Rothenberg M, Willett C, Tempero M,

- Lowy A, Abbruzzese J, Simeone D, Hingorani S, Berlin J, Tepper J. Consensus report of the national cancer institute clinical trials planning meeting on pancreas cancer treatment. *J Clin Oncol* 2009;**27**:5660-9 [PMID: 19858397 DOI: 10.1200/JCO.2009.21.9022]
27. Waddell N, Pajic M, Patch A, Chang DK, Kassahn KS, Bailey P, Johns AL, Miller D, Nones K, Quek K, Quinn MCJ, Robertson AJ, Fadlullah MZH, Bruxner TJC, Christ AN, Harliwong I, Idrisoglu S, Manning S, Nourse C, Nourbakhsh E, Wani S, Wilson PJ, Markham E, Cloonan N, Anderson MJ, Fink JL, Holmes O, Kazakoff SH, Leonard C, Newell F, Poudel B, Song S, Taylor D, Waddell N, Wood S, Xu Q, Wu J, Pinese M, Cowley MJ, Lee HC, Jones MD, Nagrial AM, Humphris J, Chantrill LA, Chin V, Steinmann AM, Mawson A, Humphrey ES, Colvin EK, Chou A, Scarlett CJ, Pinho A V, Giry-laterriere M, Rooman I, Samra JS, Kench JG, Pettitt JA, Merrett ND, Toon C, Epari K, Nguyen NQ, Barbour A, Zeps N, Jamieson NB, Graham JS, Niclou SP, Bjerkvig R, Aust D, Hruban RH, Maitra A, Iacobuzio-donahue CA, Gru R, Wolfgang CL, Morgan RA, Lawlor RT, Corbo V, Bassi C, Falconi M, Gill AJ, Eshleman JR, Pilarsky C, Scarpa A, Musgrove EA, Pearson J V, Biankin A V, Grimmond SM. Whole genomes redefine the mutational landscape of pancreatic cancer. *Nature* 2015;**518**:495-501 [DOI: 10.1038/nature14169]
28. Bailey P, Chang DK, Nones K, Johns AL, Patch A-M, Gingras M-C, Miller DK, Christ AN, Bruxner TJC, Quinn MC, Nourse C, Murtaugh LC, Harliwong I, Idrisoglu S, Manning S, Nourbakhsh E, Wani S, Fink L, Holmes O, Chin V, Anderson MJ, Kazakoff S, Leonard C, Newell F, Waddell N, Wood S, Xu Q, Wilson PJ, Cloonan N, Kassahn KS, Taylor D, Quek K, Robertson A, Pantano L, Mincarelli L, Sanchez LN, Evers L, Wu J, Pinese M, Cowley MJ, Jones MD, Colvin EK, Nagrial AM, Humphrey ES, Chantrill LA, Mawson A, Humphris J, Chou A, Pajic M, Scarlett CJ, Pinho A V., Giry-Laterriere M, Rooman I, Samra JS, Kench JG,

Lovell JA, Merrett ND, Toon CW, Epari K, Nguyen NQ, Barbour A, Zeps N, Moran-Jones K, Jamieson NB, Graham JS, Duthie F, Oien K, Hair J, Grützmann R, Maitra A, Iacobuzio-Donahue CA, Wolfgang CL, Morgan RA, Lawlor RT, Corbo V, Bassi C, Rusev B, Capelli P, Salvia R, Tortora G, Mukhopadhyay D, Petersen GM, Australian Pancreatic Cancer Genome Initiative, Munzy DM, Fisher WE, Karim SA, Eshleman JR, Hruban RH, Pilarsky C, Morton JP, Sansom OJ, Scarpa A, Musgrove EA, Bailey U-MH, Hofmann O, Sutherland RL, Wheeler DA, Gill AJ, Gibbs RA, Pearson J V., Waddell N, Biankin A V., Grimmond SM. Genomic analyses identify molecular subtypes of pancreatic cancer. *Nature* 2016;**531**:47–52 [PMID: 26909576 DOI: 10.1038/nature16965]

29. Collisson EA, Sadanandam A, Olson P, Gibb WJ, Gu S, Cooc J, Weinkle J, Kim GE, Jakkula L, Feiler HS, Ko AH, Olshen AB, Danenberg KL, Margaret A, Spellman PT, Hanahan D, Gray JW. Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. *Nat Med* 2011;**17**:500–3 [DOI: 10.1038/nm.2344.Subtypes]
30. Erkan M, Hausmann S, Michalski CW, Fingerle AA, Dobritz M. The role of stroma in pancreatic cancer : diagnostic and therapeutic implications. *Nat Rev Gastroenterol Hepatol* 2012;**9**:454–67 [DOI: 10.1038/nrgastro.2012.115]
31. Erkan M. Understanding the stroma of pancreatic cancer : co-evolution of the microenvironment with epithelial carcinogenesis. *J Pathol* 2013;**231**:4–7 [DOI: 10.1002/path.4213]
32. Koay EJ, Truty MJ, Cristini V, Thomas RM, Chen R, Chatterjee D, Kang Y, Bhosale PR, Tamm EP, Crane CH, Javle M, Katz MH, Gottumukkala VN, Rozner MA, Shen H, Lee JE, Wang H, Chen Y, Plunkett W, Abbruzzese JL, Wolff RA, Varadhachary GR, Ferrari M, Fleming JB. Transport properties of pancreatic cancer describe gemcitabine delivery and response. *J Clin Invest* 2014;**124**:1525–36

[PMID: 24614108 DOI: 10.1172/JCI73455]

33. Nordh S, Ansari D, Andersson R. hENT1 expression is predictive of gemcitabine outcome in pancreatic cancer : A systematic review. *World J Gastroenterol* 2014;**20**:8482-90 [DOI: 10.3748/wjg.v20.i26.8482]
34. Young JD, Yao SYM, Sun L, Cass CE, Baldwin S a. Human equilibrative nucleoside transporter (ENT) family of nucleoside and nucleobase transporter proteins. *Xenobiotica* [Internet] 2008;**38**:995-1021 [PMID: 18668437 DOI: 10.1080/00498250801927427] Available from: <http://www.ncbi.nlm.nih.gov/pubmed/18668437>
35. Spratlin J, Sangha R, Glubrecht D, Dabbagh L, Young JD, Dumontet C, Cass C, Lai R, Mackey JR. The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine- treated pancreas adenocarcinoma. *Clin Cancer Res* 2004;**10**:6956-61 [PMID: 15501974 DOI: 10.1158/1078-0432.CCR-04-0224]
36. Greenhalf W, Ghaneh P, Neoptolemos JP, Palmer DH, Cox TF, Lamb RF, Garner E, Campbell F, MacKey JR, Costello E, Moore MJ, Valle JW, McDonald AC, Carter R, Tebbutt NC, Goldstein D, Shannon J, Dervenis C, Glimelius B, Deakin M, Charnley RM, Lacaine F, Scarfe AG, Middleton MR, Anthony A, Halloran CM, Mayerle J, Oláh A, Jackson R, Rawcliffe CL, Scarpa A, Bassi C, Büchler MW. Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial. *J Natl Cancer Inst* 2014;**106**:20-5 [PMID: 24301456 DOI: 10.1093/jnci/djt347]
37. Soo RA, Yong W-P, Innocenti F. Systemic therapies for pancreatic cancer - the role of pharmacogenetics. *Curr Drug Targets* 2012;**13**:811-28 [PMID: 1000000221 DOI: 10.1016/j.pestbp.2011.02.012.Investigations]

38. Moffitt RA, Marayati R, Flate EL, Volmar KE, Loeza SGH, Hoadley KA, Rashid NU, Williams LA, Eaton SC, Chung AH, Smyla JK, Anderson JM, Kim HJ, Bentrem DJ, Talamonti MS, Iacobuzio-donahue CA, Hollingsworth MA, Yeh JJ. Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma. *Nat Publ Gr* 2015;**47**:1168–78 [DOI: 10.1038/ng.3398]
39. Bournet B, Selves J, Grand D, Danjoux M, Hanoun N, Cordelier P, Buscail L. Endoscopic ultrasound – guided fine-needle aspiration biopsy coupled with a KRAS mutation assay using allelic discrimination improves the diagnosis of pancreatic cancer. *J Clin Gastroenterol* 2015;**49**:50–6
40. Tempero MA, Arnoletti PJ, Behrman S, Ben-Yosef E, Benson III AB, Berlin JD. Pancreatic adenocarcinoma : clinical practice guidelines in oncology. *J Natl Compr Canc Netw* 2010;**8**:972–1017
41. O'Brien DP, Sandanayake NS, Jenkinson C, Gentry-maharaj A, Fourkala E-O, Camuzeaux S, Blyuss O, Gunu R, Zaikin A, Smith RC, Jacobs IJ, Menon U, Costello E, Stephen P. Serum CA19-9 is significantly up-regulated up to 2 years prior to diagnosis with pancreatic cancer : implications for early disease detection. *Clin Cancer Res* 2014;**22**:1734–43 [DOI: 10.1158/1078-0432.CCR-14-0365]
42. Winter JM, Yeo CJ, Brody JR. Diagnostic , Prognostic , and Predictive Biomarkers in Pancreatic Cancer. *J Surg Oncol* 2013;**107**:15–22 [DOI: 10.1002/jso.23192]
43. Pleskow DK, Berger HJ, Gyves J, Allen E, D P, Mclean A, D P, Podolsky DK. Evaluation of a Serologic Marker , CA19-9 , in the Diagnosis of Pancreatic Cancer. *Ann Intern Med* 1989;**110**:704–9
44. Berger AC, Jr MG, Hoffman JP, Regine WF, Abrams RA, Safran H, Konski A, Iii ABB, Macdonald J, Willett CG. Postresection CA 19-9 predicts overall survival in

- patients with pancreatic cancer treated with adjuvant chemoradiation : a prospective validation by RTOG 9704. *J Clin Oncol* 2008;**26**:5918–22 [DOI: 10.1200/JCO.2008.18.6288]
45. Zhang Y, Yang J, Li H, Wu Y, Zhang H, Chen W. Tumor markers CA19-9 , CA242 and CEA in the diagnosis of pancreatic cancer : a meta-analysis. *Int J Clin Exp Med* 2015;**8**:11683–91
  46. Brand RE, Nolen BM, Zeh HJ, Allen PJ, Eloubeidi MA, Goldberg M, Elton E, Arnoletti JP, Christein JD, Vickers SM, Langmead CJ, Landsittel DP, Whitcomb DC, Grizzle WE, Lokshin AE. Serum biomarker panels for the detection of pancreatic cancer. *Cancer Res* 2011;**17**:1–21 [PMID: 20402989 DOI: 10.1038/nature09421.Oxidative]
  47. Cwik G, Wallner G, Skoczylas T, Ciechanski A, Zinkiewicz K. Cancer Antigens 19-9 and 125 in the Differential Diagnosis of Pancreatic Mass Lesions. *Arch Surg* 2006;**141**:968–74
  48. Gold D V., Gaedcke J, Ghadimi BM, Goggins M, Hruban RH, Liu M, Newsome G, Goldenberg DM. PAM4 enzyme immunoassay alone and in combination with CA 19-9 for the detection of pancreatic adenocarcinoma. *Cancer* 2013;**119**:522–8 [PMID: 22898932 DOI: 10.1002/cncr.27762]
  49. Gold D V., Karanjawala Z, Modrak DE, Goldenberg DM, Hruban RH. PAM4-reactive MUC1 is a biomarker for early pancreatic adenocarcinoma. *Clin Cancer Res* 2007;**13**:7380–7 [PMID: 18094420 DOI: 10.1158/1078-0432.CCR-07-1488]
  50. Brentnall TA. Pancreatic Cancer Surveillance : Learning As We Go. *Am J Gastroenterol* [Internet] 2011;**106**:955–6 [DOI: 10.1038/ajg.2011.68] Available from: <http://dx.doi.org/10.1038/ajg.2011.68>
  51. Templeton AW, Brentnall TA. Screening and Surgical Outcomes of Familial

Pancreatic Cancer. *Surg Clin NA* 2013;**93**:629–45 [DOI: 10.1016/j.suc.2013.02.002]

52. Capurso G, Signoretti M, Valente R, Arnelo U, Lohr M, Poley J, Fave GD, Chiaro M Del, Capurso G, Signoretti M, Valente R, Valente R, Arnelo U, Lohr M, Del M. Methods and outcomes of screening for pancreatic adenocarcinoma in high-risk individuals. *World J Gastrointest Endosc* 2015;**7**:833–42 [DOI: 10.4253/wjge.v7.i9.833]
53. Laeseke PF, Chen R, Jeffrey RB, Brentnall TA, Willmann JK. Combining in vitro diagnostics with in vivo imaging for earlier detection of pancreatic ductal adenocarcinoma : challenges and solutions. *Radiology* 2015;**277**:644–61
54. Edge S, Byrd D, Compton C, Fritz A, Greene F, Trotti A. AJCC Cancer Staging Manual. 2010.
55. Saeed-vafa D, Magliocco AM. Practical Applications of Digital Pathology. *Cancer Control* 2015;**22**:137–41
56. Gurcan MN, Boucheron L, Can A, Madabhushi A, Rajpoot N, Yener B. Histopathological Image Analysis: A Review. *IEEE Rev Biomed Eng* 2009;**1**:147–71 [PMID: 20671804 DOI: 10.1109/RBME.2009.2034865.Histopathological]
57. Langer L, Binenbaum Y, Gugel L, Amit M, Gil Z, Dekel S. Computer-aided diagnostics in digital pathology: automated evaluation of early-phase pancreatic cancer in mice. *Int J Comput Assist Radiol Surg* [Internet] 2015;**10**:1043–54 [PMID: 25354901 DOI: 10.1007/s11548-014-1122-9] Available from: <http://dx.doi.org/10.1007/s11548-014-1122-9>
58. Song J, Lee J. New morphological features for grading pancreatic ductal adenocarcinomas. *Biomed Res Int* 2013;**1**–25
59. Song JW, Lee JH, Choi JH, Chun SJ. Automatic differential diagnosis of pancreatic serous and mucinous cystadenomas based on morphological features. *Comput Biol*

- Med* [Internet] 2013;**43**:1-15 [PMID: 23200461 DOI: 10.1016/j.combiomed.2012.10.009] Available from: <http://dx.doi.org/10.1016/j.combiomed.2012.10.009>
60. Pantanowitz L, Sinard JH, Henricks WH, Fatheree LA, Carter AB, Contis L, Beckwith BA, Evans AJ, Otis CN, Lal A, Parwani A V. Validating whole slide imaging for diagnostic purposes in pathology: guideline from the college of american pathologists pathology and laboratory quality center. *Arch Pathol Lab Med* 2013;**137**:1710-22 [PMID: 23634907 DOI: 10.5858/arpa.2013-0093-CP]
  61. Anderson N, Badano A. Technical performance assessment of digital pathology whole slide imaging devices [Internet]. Guid. Ind. Food Drug Adm. Staff 2016; Available from: <http://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/UCM435355.pdf>
  62. Morroney R. FDA intends to reclassify digital pathology systems. *Inspirata* [Internet] 2016; Available from: <http://www.inspirata.com/fda-intends-to-reclassify-digital-pathology-systems/>
  63. Harsha HC, Kandasamy K, Ranganathan P, Rani S, Ramabadrans S, Gollapudi S, Balakrishnan L, Dwivedi SB, Telikicherla D, Selvan LDN, Goel R, Mathivanan S, Marimuthu A, Kashyap M, Vizza RF, Mayer RJ, DeCaprio JA, Srivastava S, Hanash SM, Hruban RH, Pandey A. A compendium of potential biomarkers of pancreatic cancer. *PLoS Med* 2009;**6**:2-7 [PMID: 19360088 DOI: 10.1371/journal.pmed.1000046]
  64. Rhim AD, Mirek ET, Aiello NM, Maitra A, Jennifer M, McCallister F, Reichert M, Beatty GL, Anil K, Vonderheide RH, Leach SD, Stanger BZ. EMT and dissemination precede pancreatic tumor formation. *Cell* 2012;**148**:349-61 [DOI: 10.1016/j.cell.2011.11.025.EMT]

65. Mani SA, Guo W, Liao M, Eaton EN, Zhou AY, Brooks M, Reinhard F, Zhang CC, Campbell LL, Polyak K, Brisken C, Yang J, Weinberg RA. The epithelial-mesenchymal transition generates cells with properties of stem cells. *Cell* 2008;**133**:704–15 [DOI: 10.1016/j.cell.2008.03.027.The]
66. Tjensvoll K, Nordga O, Smaaland R. Circulating tumor cells in pancreatic cancer patients: Methods of detection and clinical implications. *Int J Cancer* 2014;**134**:1–8 [DOI: 10.1002/ijc.28134]
67. De Giorgi U, Valero V, Rohren E, Dawood S, Ueno NT, Miller MC, Doyle G V, Jackson S, Andreopoulou E, Handy BC, Reuben JM, Fritsche HA, Macapinlac HA, Hortobagyi GN, Cristofanilli M. Circulating Tumor Cells and Fluorodeoxyglucose Positron Emission Tomography / Computed Tomography for Outcome Prediction in Metastatic Breast Cancer. *J Clin Oncol* 2009;**27**:3303–11 [DOI: 10.1200/JCO.2008.19.4423]
68. Cristofanilli M, Budd T, Ellis MJ, Stopeck A, Matera J, Ph R, Miller MC, Reuben JM, Doyle G V, Allard WJ, Terstappen LWMM, Hayes DF. Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer. *N Engl J Med* 2004;**351**:781–91
69. Bono JS De, Scher HI, Montgomery RB, Parker C, Miller MC, Tissing H, Doyle G V, Terstappen LWMM, Pienta KJ, Raghavan D. Circulating Tumor Cells Predict Survival Benefit from T reatment in Metastatic Castration-Resistant Prostate Cancer. *Clin Cancer Res* 2008;**14**:6302–9 [DOI: 10.1158/1078-0432.CCR-08-0872]
70. Cohen SJ, Punt CJA, Iannotti N, Saidman BH, Sabbath KD, Gabrail NY, Picus J, Morse M, Mitchell E, Miller MC, Doyle G V, Tissing H, Terstappen LWMM, Meropol NJ. Relationship of Circulating Tumor Cells to Tumor Response , Progression-Free Survival , and Overall Survival in Patients With Metastatic Colorectal Cancer. *J Clin Oncol* 2008;**26**:3213–22 [DOI: 10.1200/JCO.2007.15.8923]

71. Krebs MG, Sloane R, Priest L, Lancashire L, Hou J, Greystoke A, Ward TH, Ferraldeschi R, Hughes A, Clack G, Ranson M, Dive C, Blackhall FH. Evaluation and Prognostic Significance of Circulating Tumor Cells in Patients With Non - Small-Cell Lung Cancer. *J Clin Oncol* 2011;**29**:1556-63 [DOI: 10.1200/JCO.2010.28.7045]
72. Miyazono F, Takao S, Natsugoe S, Uchikura K, Kijima F, Aridome K, Shinchi H, Aikou T. Molecular Detection of Circulating Cancer Cells during Surgery in Patients with Biliary-Pancreatic Cancer. *Am J Surg* 1999;**177**:475-9
73. De Albuquerque A, Kubisch I, Breier G, Stamminger G, Fersis N, Eichler A, Kaul S, Stolzel U. Multimarker Gene Analysis of Circulating Tumor Cells in Pancreatic Cancer Patients : A Feasibility Study. *Oncology* 2012;**82**:3-10 [DOI: 10.1159/000335479]
74. Bobek V, Gurlich R, Eliasova P, Kolostova K. Circulating tumor cells in pancreatic cancer patients : Enrichment and cultivation. *World J Gastroenterol* 2014;**20**:17163-70 [DOI: 10.3748/wjg.v20.i45.17163]
75. Riva F, Dronov OI, Khomenko DI, Huguet F, Louvet C, Mariani P, Stern M, Lantz O, Proudhon C, Pierga J, Bidard F. Clinical applications of circulating tumor DNA and circulating tumor cells in pancreatic cancer. *Mol Oncol* 2016;**10**:481-93 [DOI: 10.1016/j.molonc.2016.01.006]
76. Nagrath S, Jack RM, Sahai V, Simeone DM. Opportunities and Challenges for Circulating Pancreatic Tumor Cells. *Gastroenterology* 2016;**16** [DOI: 10.1053/j.gastro.2016.05.052]
77. Allard WJ, Matera J, Miller MC, Repollet M, Connelly MC, Rao C, Tibbe AGJ, Uhr JW, Terstappen LWMM. Tumor Cells Circulate in the Peripheral Blood of All Major Carcinomas but not in Healthy Subjects or Patients With Nonmalignant

Diseases. *Clin Cancer Res* 2004;**10**:6897-904

78. Bidard FC, Huguet F, Louvet C, Mineur L, Bouché O, Chibaudel B, Artru P, Desseigne F, Bachet JB, Mathiot C, Pierga JY, Hammel P. Circulating tumor cells in locally advanced pancreatic adenocarcinoma : the ancillary CirCe 07 study to the LAP 07 trial. *Ann Oncol* 2013;**24**:2057-61 [DOI: 10.1093/annonc/mdt176]
79. Khoja L, Backen A, Sloane R, Menasce L, Ryder D, Krebs M, Board R, Clack G, Hughes A, Blackhall F, Valle JW, Dive C. A pilot study to explore circulating tumour cells in pancreatic cancer as a novel biomarker. *Br J Cancer* 2012;**106**:508-16 [DOI: 10.1038/bjc.2011.545]
80. Bissolati M, Sandri MT, Burtulo G, Zorzino L, Balzano G, Braga M. Portal vein-circulating tumor cells predict liver metastases in patients with resectable pancreatic cancer. *Tumor Biol* 2015;**36**:991-6 [DOI: 10.1007/s13277-014-2716-0]
81. Kurihara T, Itoi T, Sofuni A, Itokawa F, Tsuchiya T, Tsuji S, Ishii K, Ikeuchi N, Tsuchida A, Kasuya K, Kawai T, Sakai Y, Moriyasu F. Detection of circulating tumor cells in patients with pancreatic cancer : a preliminary result. *J Hepatobiliary Pancreat Surg* 2008;**15**:189-95 [DOI: 10.1007/s00534-007-1250-5]
82. Earl J, Garcia-nieto S, Martinez-avila JC, Montans J, Sanjuanbenito A, Rodríguez-garro M, Lisa E, Mendía E, Lobo E, Malats N, Carrato A, Guillen-ponce C. Circulating tumor cells ( Ctc ) and kras mutant circulating free Dna ( cfdna ) detection in peripheral blood as biomarkers in patients diagnosed with exocrine pancreatic cancer. *BMC Cancer* 2015;**15**:1-10 [DOI: 10.1186/s12885-015-1779-7]
83. Parkinson DR, Dracopoli N, Gumbs Petty B, Compton C, Cristofanilli M, Deisseroth A, Hayes DF, Kapke G, Kumar P, Lee JS, Liu MC, McCormack R, Mikulski S, Nagahara L, Pantel K, Pearson-White S, Punnoose E a, Roadcap LT, Schade AE, Scher HI, Sigman CC, Kelloff GJ. Considerations in the development

- of circulating tumor cell technology for clinical use. *J Transl Med* [Internet] 2012;**10**:138 [PMID: 22747748 DOI: 10.1186/1479-5876-10-138] Available from: Journal of Translational Medicine
84. Vona G, Sabile A, Louha M, Sitruk V, Romana S, Franco D, Pazzagli M, Vekemans M, Lacour B, Brechot C, Paterlini-Brechot P. Isolation by size of epithelial tumor cells: a new method for the immunomorphological and molecular characterization of circulating tumor cells. *Am J Pathol* 2000;**156**:57–63
  85. Paterlini-Bréchot P. Circulating Tumor Cells : Who is the Killer ? *Cancer Microenviron* 2014;**7**:161–76 [DOI: 10.1007/s12307-014-0164-4]
  86. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. *Nat Rev Cancer* 2002;**2**:442–54 [DOI: 10.1038/nrc822]
  87. Went PTH, Lugli A, Meier S, Bundi M, Mirlacher M, Sauter G, Dirnhöfer S. Frequent EpCam Protein Expression in Human Carcinomas. *Hum Pathol* 2004;**35**:122–8 [DOI: 10.1016/S0046-8177(03)00502-1]
  88. Ren C, Han C, Zhang J, He P, Wang D, Zhao P, Zhao X. Detection of apoptotic circulating tumor cells in advanced pancreatic cancer following 5-fluorouracil chemotherapy. *Cancer Biol Ther* 2011;**12**:700–6 [DOI: 10.4161/cbt.12.8.15960]
  89. Court CM, Ankeny JS, Sho S, Hou S, Li Q, Hsieh C, Song M, Liao X, Rochefort MM, Wainberg Z, Graeber TG, Tseng H, Tomlinson JS. Reality of Single Circulating Tumor Cell Sequencing for Molecular Diagnostics in Pancreatic Cancer. *J Mol Diagnostics* 2016;**1**–10 [DOI: 10.1016/j.jmoldx.2016.03.006]
  90. Chausovsky G, Luchansky M, Figer A, Shapira J, Gottfried M, Novis B, Bogelman G, Zemer R, Zimlichman S, Klein A. Expression of cytokeratin 20 in the blood of patients with disseminated carcinoma of the pancreas, colon, stomach, and lung. *Cancer* 1999;**86**:2398–405

91. Soeth E, Grigoleit U, Moellmann B, Roder C, Schniewind B, Kremer B, Kalthoff H, Vogel I. Detection of tumor cell dissemination in pancreatic ductal carcinoma patients by CK 20 RT-PCR indicates poor survival. *J Cancer Res Clin Oncol* 2005;**131**:669–76 [PMID: 16136352 DOI: 10.1007/s00432-005-0008-1]
92. Chu P, Ph D, Wu E, Weiss LM. Cytokeratin 7 and Cytokeratin 20 Expression in Epithelial Neoplasms : A Survey of 435 Cases. *Mod Pathol* 2000;**13**:962–72
93. Zhou J, Hu L, Yu Z, Zheng J, Yang D, Bouvet M, Hoffman RM. Marker expression in circulating cancer cells of pancreatic cancer patients. *J Surg Res* 2011;**171**:631–6 [PMID: 20869080 DOI: 10.1016/j.jss.2010.05.007]
94. Ankeny JS, Hou S, Lin M, OuYang H, Song M, Rochefort MM, Girgis MD, Isacoff WH, Wainberg ZA, Tseng H-R, Tomlinson JS. Pancreatic circulating tumor cells as a diagnostic adjunct in pancreatic cancer. In: *J Clin Oncol*. page Abstract 175
95. Yu M, Ting DT, Stott SL, Wittner BS, Ozsolak F, Paul S, Ciciliano JC, Smas ME, Winokur D, Gilman AJ, Ulman MJ, Xega K, Contino G, Alagesan B, Brannigan BW, Milos PM, Ryan DP, Sequist L V, Bardeesy N, Ramaswamy S, Toner M, Maheswaran S, Haber DA. RNA sequencing of pancreatic circulating tumour cells implicates WNT signalling in metastasis. *Nature* 2012;**487**:510–3 [DOI: 10.1038/nature11217]
96. Ting DT, Wittner BS, Ligorio M, Jordan NV, Ajay M, Miyamoto DT, Aceto N, Bersani F, Brian W, Xega K, Ciciliano JC, Zhu H, Mackenzie OC, Trautwein J, Arora KS, Shahid M, Ellis HL, Qu N, Bardeesy N, Rivera MN, Deshpande V, Ferrone CR, Ramaswamy S, Shioda T, Toner M, Maheswaran S, Haber DA. Single-cell RNA sequencing identifies extracellular matrix gene expression by pancreatic circulating tumor cells. *Cell Rep* 2014;**8**:1905–18 [DOI: 10.1016/j.celrep.2014.08.029.Single-Cell]

97. Lohr JG, Adalsteinsson VA, Cibulskis K, Choudhury AD, Rosenberg M, Cruz-gordillo P, Francis JM, Zhang C, Shalek AK, Satija R, Trombetta JJ, Lu D, Tallapragada N, Tahirova N, Kim S, Blumenstiel B, Sougnez C, Lowe A, Wong B, Auclair D, Allen EM Van, Nakabayashi M, Lis RT, Lee GM, Li T, Chabot MS, Ly A, Taplin M, Clancy TE, Loda M, Regev A, Meyerson M, Hahn WC, Kantoff PW, Golub TR, Getz G, Boehm JS, Love JC. Whole-exome sequencing of circulating tumor cells provides a window into metastatic prostate cancer. *Nat Biotechnol* 2014;**32**:479–84 [DOI: 10.1038/nbt.2892]
98. Witkiewicz AK, Mcmillan EA, Balaji U, Baek G, Lin W, Mansour J, Mollae M, Wagner K, Koduru P, Yopp A, Choti MA, Yeo CJ, Mccue P, White MA, Knudsen ES. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. *Nat Commun* 2015;**6**:1–11 [DOI: 10.1038/ncomms7744]
99. Jiao Y, Yonescu R, Offerhaus GJA, Klimstra DS, Eshleman JR, Herman JG, Poh W, Pelosof L, Wolfgang CL, Vogelstein B, Kinzler KW, Hruban RH, Papadopoulos N, Wood LD. Whole exome sequencing of pancreatic neoplasms with acinar differentiation. *J Pathol* 2014;**232**:428–35 [DOI: 10.1002/path.4310.Whole]
100. Berger AW, Schwerdel D, Costa IG, Hackert T, Strobel O, Lam S, Barth TF, Schröppel B, Meining A, Büchler MW, Zenke M, Hermann PC, Seufferlein T, Kleger A. Detection of Hot-Spot Mutations in Circulating Cell-Free DNA From Patients With Intraductal Papillary Mucinous Neoplasms of the Pancreas. *Gastroenterology* [Internet] 2016;**1**–4 [DOI: 10.1053/j.gastro.2016.04.034] Available from: <http://dx.doi.org/10.1053/j.gastro.2016.04.034>
101. Harewood GC, Wiersema MJ. A cost analysis of endoscopic ultrasound in the evaluation of pancreatic head adenocarcinoma. *Am J Gastroenterol* 2001;**96**:2651–6 [PMID: 11569690 DOI: 10.1111/j.1572-0241.2001.04116.x]
102. CMS.gov. 2015 Medicare Clinical Laboratory Fee Schedule. [Internet]. Cent.

Medicare Medicaid2015;Available from:

<https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/ClinicalLabFeeSched/clinlab.html>

103. Verma M, Lam TK, Hebert E, Divi RL. Extracellular vesicles : potential applications in cancer diagnosis , prognosis , and epidemiology. *BMC Clin Pathol* 2015;**15**:1-9 [DOI: 10.1186/s12907-015-0005-5]
104. Nabhan JF, Hu R, Oh RS, Cohen SN, Lu Q. Formation and release of arrestin domain-containing protein 1-mediated microvesicles ( ARMMs ) at plasma membrane by recruitment of TSG101 protein. *PNAS* 2012;**109**:41464151 [DOI: 10.1073/pnas.1200448109/- /DCSupplemental.www.pnas.org/cgi/doi/10.1073/pnas.1200448109]
105. Taylor DD, Gercel-Taylor C. Exosomes / microvesicles : mediators of cancer-associated immunosuppressive microenvironments. *Semin Immunopathol* 2011;**33**:441-54 [DOI: 10.1007/s00281-010-0234-8]
106. Robinson SM, Fan L, White SA, Charnley RM. The role of exosomes in the pathogenesis of pancreatic ductal adenocarcinoma. *Int J Biochem Cell Biol* 2016;**1**-9
107. Munson P, Shukla A. Exosomes: Potential in Cancer Diagnosis and Therapy. *Medicines* 2015;**2**:310-27 [DOI: 10.3390/medicines2040310]
108. An T, Qin S, Xu Y, Tang Y, Huang Y, Situ B, Inal JM, Zheng L. Exosomes serve as tumour markers for personalized diagnostics owing to their important role in cancer metastasis. *J Extracell Vesicles* 2015;**4**:1-15
109. Hidalgo M, Plaza C, Musteanu M, Illei P, Brachmann CB. SPARC Expression Did Not Predict Efficacy of nab -Paclitaxel Plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT Trial. *Clin Cancer Res* **5000**

110. Sheridan C. Exosome cancer diagnostic reaches market. *Nat Biotechnol* 2016;**34**:359–60 [DOI: 10.1038/nbt0416-359]
111. Baietti MF, Zhang Z, Mortier E, Melchior A, Degeest G, Geeraerts A, Ivarsson Y, Depoortere F, Coomans C, Vermeiren E, Zimmermann P, David G. Syndecan – syntenin – ALIX regulates the biogenesis of exosomes. *Nat Cell Biol* 2012;**14**:677–85 [DOI: 10.1038/ncb2502]
112. Melo SA, Luecke LB, Kahlert C, Fernandez AF, Gammon ST, Kaye J, Lebleu VS, Mittendorf EA, Weitz J, Rahbari N, Reissfelder C, Pilarsky C, Fraga MF, Piwnicka-worms D, Kalluri R. Glypican-1 identifies cancer exosomes and detects early pancreatic cancer. *Nature* 2015;**523**:177–82 [DOI: 10.1038/nature14581]
113. Siveke JT, Crawford HC. KRAS above and beyond - EGFR in pancreatic cancer. *Oncotarget* [Internet] 2012;**3**:9–10 [PMID: 23174662 DOI: 10.18632/oncotarget.750] Available from: <http://www.ncbi.nlm.nih.gov/pubmed/23174662>
114. Adamczyk KA, Klein-scory S, Moradian M, Warnken U, Schmiegel W, Schnölzer M, Schwarte-waldhoff I. Characterization of soluble and exosomal forms of the EGFR released from pancreatic cancer cells. *Life Sci* 2011;**89**:304–12 [DOI: 10.1016/j.lfs.2011.06.020]
115. Ciravolo V, Huber V, Ghedini GC, Venturelli E, Bianchi F, Campiglio M, Morelli D, Villa A, Mina P Della, Menard S, Filipazzi P, Rivoltini L, Tagliabue E, Pupa SM. Potential Role of Exosomes in Countering Trastuzumab-Based Therapy. *J Cell Physiol* 2011;**227**:658–67 [DOI: 10.1002/jcp.22773]
116. Smit VTHBM, Boot AJM, Jan Fleuren G, Cprenlisse CJ, Bos JL. KRAS codon 12 mutations occur very frequently in pancreatic adenocarcinomas. *Nucleic Acids Res* 1988;**16**:7773–82

117. Almoguera C, Shibata D, Forrester K, Martin J, Arnheim N, Perucho M. Most Human Carcinomas of the Exocrine Contain Mutant c-K-ras Genes. *Cell* 1988;**53**:549-54
118. Kahlert C, Melo SA, Protopopov A, Tang J, Seth S, Koch M, Zhang J, Weitz J, Chin L, Futreal A. Identification of Double- stranded Genomic DNA Spanning All Chromosomes with Mutated KRAS and p53 DNA in the Serum Exosomes. 2014;**289**:3869-75 [DOI: 10.1074/jbc.C113.532267]
119. San Lucas FA, Allenson K, Bernard V, Castillo J, Kim DU, Ellis K, Ehli EA, Davies GE, Petersen JL, Li D, Wolff R, Katz M, Varadhachary G, Wistuba I, Maitra A, Alvarez H. Minimally invasive genomic and transcriptomic profiling of visceral cancers by next-generation sequencing of circulating exosomes. *Ann Oncol* 2016;**27**:635-41 [PMID: 26681674 DOI: 10.1093/annonc/mdv604]
120. Charrier A, Chen R, Chen L, Kemper S, Hattori T, Takigawa M, Brigstock DR. Connective tissue growth factor (CCN2) and microRNA-21 are components of a positive feedback loop in pancreatic stellate cells (PSC) during chronic pancreatitis and are exported in PSC-derived exosomes. *J Cell Commun Signal* 2014;**8**:147-56 [PMID: 24464300 DOI: 10.1007/s12079-014-0220-3]
121. Ding G, Zhou L, Qian Y, Fu M, Chen J, Chen J, Xiang J, Wu Z, Jiang G, Cao L. Pancreatic cancer-derived exosomes transfer miRNAs to dendritic cells and inhibit RFXAP expression via miR-212-3p. *Oncotarget* [Internet] 2015;**6**:29877-88 [PMID: 26337469 DOI: 10.18632/oncotarget.4924] Available from: <http://europepmc.org/articles/PMC4745769/?report=abstract>
122. Patel GK, Patton MC, Singh S, Ajay P. Pancreatic Cancer Exosomes: Shedding Off for a Meaningful Journey. *Pancreat Disord Ther* 2016;**6**:e148 [DOI: 10.4172/2165-7092.1000e148.Pancreatic]

123. Que R, Ding G, Chen J, Cao L. Analysis of serum exosomal microRNAs and clinicopathologic features of patients with pancreatic adenocarcinoma. *World J Surg Oncol* [Internet] 2013;**11**:1-9 [DOI: 10.1186/1477-7819-11-219] Available from: World Journal of Surgical Oncology
124. Christianson HC, Svensson KJ, Kuppevelt TH Van, Li J, Belting M. Cancer cell exosomes depend on cell-surface heparan sulfate proteoglycans for their internalization and functional activity. *PNAS* 2013;**110**:17380-5 [DOI: 10.1073/pnas.1304266110/- /DCSupplemental.www.pnas.org/cgi/doi/10.1073/pnas.1304266110]
125. Hoshino A, Costa-silva B, Shen T, Rodrigues G, Hashimoto A, Mark MT, Molina H, Kohsaka S, Giannatale A Di, Ceder S, Singh S, Williams C, Soplol N, Uryu K, Pharmed L, King T, Bojmar L, Davies AE, Ararso Y, Zhang T, Zhang H, Hernandez J, Weiss JM, Dumont-cole VD, Kramer K, Wexler LH. Tumour exosome integrins determine organotropic metastasis. *Nature* 2015;**527**:329-35 [DOI: 10.1038/nature15756]
126. Mulcahy LA, Pink RC, Raul D, Carter F. Routes and mechanisms of extracellular vesicle uptake. *J Extracell Vesicles* 2014;**3**:1-14
127. Costa-silva B, Aiello NM, Ocean AJ, Singh S, Zhang H, Thakur BK, Becker A, Hoshino A, Mark MT, Molina H, Xiang J, Zhang T, Theilen T, García-santos G, Williams C, Ararso Y, Huang Y, Rodrigues G, Shen T, Labori KJ, Marie I, Lothe B, Kure EH, Hernandez J, Doussot A, Ebbesen SH. Pancreatic cancer exosomes initiate pre-metastatic niche formation in the liver. *Nat Cell Biol* 2015;**17**:816-26 [DOI: 10.1038/ncb3169]
128. Wang F, Herrington M, Larsson J, Permert J. The relationship between diabetes and pancreatic cancer. *Mol Cancer* 2003;**2**:1-5

129. Javeed N, Sagar G, Dutta SK, Smyrk TC, Lau JS, Bhattacharya S, Truty M, Petersen GM, Kaufman RJ, Suresh T. Pancreatic Cancer-derived Exosomes Causes Paraneoplastic  $\beta$ - cell Dysfunction. *Clin Cancer Res* 2015;**21**:1722–33 [DOI: 10.1158/1078-0432.CCR-14-2022.Pancreatic]
130. Que R, Ding G, Chen J, Cao L. Analysis of serum exosomal microRNAs and clinicopathologic features of patients with pancreatic adenocarcinoma. *World J Surg Oncol* 2013;**11**:1–9 [DOI: 10.1186/1477-7819-11-219]

Table 1. Clinical uses for biomarker panels that increase predictive value of CA-19-9 for pancreatic cancer. \*Values reflect subjects presented with pancreatobiliary disease. Endoscopic ultrasound and fine needle aspiration (EUS-FNA), osteoprotegerin (OPG), intercellular adhesion molecule 1 (ICAM-1), carcinoembryonic antigen (CEA), tissue inhibitor of metalloproteinases 1 (TIMP-1), clivatuzumab monoclonal antibody (PAM4) to MUC5AC.

	<b>CA 19-9</b>	Sensitivity	Specificity	Reference
<b>Screening in population</b>	EUS-FNA	75-94%	78-95%	[39]
	CA 19-9*	60-70%	70-85%	[42][43]
<b>Differential diagnosis</b>	CA 19-9	60%	83%	[41]
	CA 19-9 + CA 125	87%	77%	[41]
	CA 19-9 + ICAM-1 + OPG	78%	94%	[46]
	CA 19-9 + CEA + TIMP-1	71%	89%	[46]
<b>Staging</b>	PAM4-reactive mucins	76%	85%	[48]
	CA 19-9 + PAM4-reactive mucins	84%	82%	[48]
<b>Monitor treatment</b>	Response to chemotherapy			[44]
<b>Monitor Recurrence</b>	Low levels post-surgery correlate with survival			[42]

Table 2. Summary of demonstrated clinical uses for digital pathology, circulating tumor cells and extracellular vesicles for pancreatic cancer.

	<b>Digital Pathology</b>	<b>Circulating Tumor Cells (CTCs)</b>	<b>Extracellular Vesicles (EVs)</b>
<b>Screening in population</b>	Relies on invasive biopsies	Detection of KRAS mutations <sup>[89]</sup>	Early detection possibility (GPC1+ EVs) <sup>[112]</sup>
<b>Diagnosis</b>	Differential diagnosis of mucinous cancers <sup>[59]</sup>	Pancreatic CTC detected by ISET <sup>[79]</sup> and CellSearch <sup>[78]</sup>	GPC1+ EVs detects IPMNs <sup>[112]</sup> EVs express mutated KRAS and p53 in PDAC serum <sup>[118]</sup> EVs detect pancreaticobiliary cancers <sup>[119]</sup>
<b>Staging</b>	Early stage detection in mice <sup>[57]</sup> Distinguish Grade I/II in humans <sup>[58]</sup>	(C-MET, CK20, CEA)+ CTCs elevated in late stages <sup>[93]</sup>	miR-17-5p in serum exosomes correlates with stage <sup>[130]</sup>
<b>Prognosis</b>	potential	CTC positivity has prognostic value in LAPC <sup>[78]</sup> CK20 expression in CTC indicates shorter overall survival <sup>[91]</sup>	potential
<b>Monitor treatment</b>	potential	CTC detection decreases during 5-FU therapy <sup>[88]</sup>	potential
<b>Drug sensitivity/ pharmacokinetics</b>	CT scans can predict drug transport <sup>[32]</sup>	CTC apoptosis can be detected after 5-FU therapy <sup>[88]</sup>	Demonstrated for breast cancer <sup>[111]</sup>
<b>Monitor Recurrence</b>	potential	Positivity correlates with postoperative staging <sup>[91][94]</sup>	potential

Table 3. Challenges and potential solutions for pancreatic cancer diagnosis and treatment

Challenges	Potential Solutions
Metastatic probability increases dramatically with larger tumor size	Promote development of early detection methods (circulating tumor cells, extracellular vesicles, molecular cargo in CTCs and EVs, cfDNA, ctDNA)
Tumor mutations take up to two decades to develop, metastatic mutations are heterogeneous and occur late in the process	Identify founder mutations that correlate with unusual survival outcomes
Pancreatic stroma affects prognosis and treatment sensitivity	Promote research on stromal characterization
Transporter expression in the tumor impacts drug delivery	Identify features that correlate with treatment sensitivity to a variety of drugs
CA 19-9 is not pancreatic cancer specific	Promote development of assays for biomarker panels that increase CA 19-9 utility and pave the way for FDA approval
Prediction of resectability is only 70-85% accurate	Improve staging based on biopsies by implementing clinical use of digital pathology methods
No FDA-approved digital pathology methods exist for pancreatic cancer	Combine digital pathology with accepted primary diagnostic methods Test special controls for digital imaging that will permit FDA application through a more streamlined <i>de novo</i> application pathway

